Farnesyl thiosalicylic acid amide  (Synonyms: FTS amide; Salirasib amide)

Farnesyl thiosalicylic acid amide (FTS-A) is an orally active derivative of farnesyl thiosalicylic acid (HY-14754). Farnesyl thiosalicylic acid amide reduces Ras-GTP levels and inhibits cell growth with IC₅₀s of 20 and 10 μM for Panc-1 and U87 cells, respectively. Farnesyl thiosalicylic acid amide can be used for the research of cancer^[1].

Farnesyl thiosalicylic acid amide (50 μM, 24 h) decreases the levels of total Ras-GTP and K-Ras-GTP in Panc-1 and U87 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Farnesyl thiosalicylic acid amide (100 mg/kg, i.g., once time) inhibits tumor growth in Panc-1 nude mouse model^[1].
Farnesyl thiosalicylic acid amide (100 mg/kg, p.o., twice a day, 14 days) inhibits tumor growth in U87 nude mouse model^[1].

Pharmacokinetic Analysis in Panc-1 Nude Mouse Model^[1]

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

357.55

C₂₂H₃₁NOS

1092521-74-8

C/C(C)=C/CC/C(C)=C/CC/C(C)=C/CSC1=C(C=CC=C1)C(N)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Goldberg L, et al. New derivatives of farnesylthiosalicylic acid (salirasib) for cancer treatment: farnesylthiosalicylamide inhibits tumor growth in nude mice models. J Med Chem. 2009 Jan 8;52(1):197-205.  [Content Brief]